Hauwa Ali Abdul
When in October 2025 the World Health Organization announced that effective malaria vaccines were finally being rolled out in 24 African countries, the news struck like a long-awaited dawn after centuries of darkness. For a continent that still shoulders about 94 percent of global malaria cases, it was not merely a scientific milestone—it was a sigh of relief, a profound shift in Africa’s public-health landscape.
In busy clinics from Accra to Kano, mothers who once watched their children writhing through repeated fevers may now hold hope in a new form of protection. Yet while the vaccine’s arrival matters, it also illuminates the challenges: many African health systems remain under pressure, and the broader fight against malaria, caused by poor sanitation, infrastructure and poverty, is far from over.
Malaria is in many parts of Africa not just another disease; it is a generational-wound. According to WHO’s most recent reports, the African region carried nearly all of the world’s malaria deaths. Despite long-running campaigns of insecticide-treated nets, indoor spraying and community outreach, malaria remains resilient. Insecticide resistance is now widespread across many African countries, and concerns about emerging parasite resistance to frontline treatments are growing.
As the WHO’s regional director in Africa, Dr Matshidiso Moeti, put it at the time of the vaccine recommendation:
“For centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering… We have long hoped for an effective malaria vaccine and now for the first time ever, we have such a vaccine recommended for widespread use. Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease.”
Those words capture both the relief and the challenge. The burden remains enormous and the terrain hostile. In many parts of Africa, sanitation systems are minimal, drainage is poor, and housing remains vulnerable—making mosquito breeding impossible to eliminate even when control measures are in place.
The first malaria vaccine, called RTS,S/AS01 (branded Mosquirix), earned WHO recommendation after decades of research and pilot implementation in Ghana, Kenya and Malawi. The evaluation of the pilot programme (the Malaria Vaccine Implementation Programme, MVIP) found that among children eligible for vaccination, all-cause mortality fell by about 13 % and severe malaria hospitalisations dropped significantly.
Meanwhile, a second vaccine, R21/Matrix‑M, developed by Oxford and the Serum Institute of India, is under review and expected to further expand supply.
In November 2023, shipments of RTS,S began to countries beyond the original pilots, signalling a broad roll-out across Africa. As WHO and the Gavi, the Vaccine Alliance put it:
“The world needs good news – and this is a good news story,” said David Marlow, CEO of Gavi.
“Introducing vaccines [against malaria] is like adding a star player to the pitch… With this long-anticipated step, spearheaded by African leaders, we are entering a new era in immunisation and malaria control, hopefully saving the lives of hundreds of thousands of children every year.” — Catherine Russell, UNICEF Executive Director.
Read Also: The Nsabe Public Health Weekly: Where Real-life Stories Meet Public Health Insights
For health officials in Nigeria, this moment is not abstract. According to public briefing documents, Nigeria’s health ministry sees the vaccine as a major new tool in its malaria control arsenal and a complement to existing interventions.
Why Malaria Control Has Been So Difficult
The battle against malaria in Africa has always been fought under severely disadvantageous conditions. Many rural areas suffer from inadequate drainage, open gutters and standing water, creating mosquito breeding grounds. Rapid urbanisation, often without sufficient sanitation infrastructure, makes matters worse. In cities like Lagos, Kinshasa or Dar es Salaam, informal settlements with poor waste collection and limited clean water supply enable malaria’s persistence day after day.
The link between poverty and malaria is deeply cyclical: illness costs money, and poverty increases vulnerability. The African Union estimates malaria costs the continent around US$12 billion annually in lost productivity and healthcare expenditure.
Public-health experts emphasise that vaccines alone won’t end malaria. As one regional researcher explained: you must combine vaccination with improvements in sanitation, housing and infrastructure. Without those, mosquito control remains incomplete.
The malaria vaccine arrives at a time when African health systems face multiple simultaneous crises—outbreaks of cholera, mpox, measles, the lingering impact of COVID-19, frequent strikes among health-workers and chronic infrastructure shortfalls. In the Democratic Republic of Congo, for example, one-third of mpox vaccine donations from Japan went unused because of cold chain and logistics failures.
That raises key questions: Can over-burdened systems manage a new mass-vaccination campaign, especially for a four-dose schedule? The WHO and Gavi say yes, but only if rollout is integrated into existing routine immunisation programmes, the cold-chain is strengthened, health-workers are trained, and community engagement is high.
In conflict-affected settings—northern Nigeria, parts of Mali or South Sudan, large numbers of children remain unreachable. And in some rural communities, vaccine hesitancy persists due to misinformation. Health-system strain is real, but many experts see the vaccine campaign as an opportunity to strengthen primary health care at the same time.
Communities on the Frontline
In Ghana’s Ashanti Region, where the pilot RTS,S was introduced, early observational reports from clinics suggest fewer severe malaria cases in vaccinated children. Health-workers in those regions describe lighter disease burden and fewer emergency admissions. Data from the pilot supports this: severe malaria hospitalisations dropped by roughly 22 % in those areas.
In Nigeria’s Kano State, health-workers report high demand for the vaccine where malaria remains a daily threat. Families routinely lose children to the disease or endure frequent spells of illness. The vaccine is being welcomed as a long-awaited protection.
These grassroots responses matter because they reflect trust, demand and real-world change—not just laboratory results.
Experts say the malaria vaccine rollout offers more than disease-specific gains—it can help build stronger primary-health infrastructure in Africa. Vaccination programmes bring children into clinics, strengthen data systems, improve supply chains, and build trust in public-health services.
WHO Regional Director Dr Moeti described this as: “a vital addition to the existing set of malaria prevention tools … [that] will help bolster our efforts to reverse the rising trend in cases and further reduce deaths.”
In Nigeria, for instance, the government is combining multiple vaccinations—measles, rubella, polio and now malaria—in integrated campaigns. That kind of approach reduces missed opportunities, lowers cost per-child, and ties the malaria-vaccine rollout into existing child-health systems rather than treating it as a stand-alone intervention.
Funding, Equity, and the Future
The success of the malaria-vaccine campaign will depend heavily on financing and equitable access. Initial rollout is supported by donors such as Gavi, WHO and UNICEF, but long-term sustainability means countries will need to co-finance doses, develop procurement systems, and ensure supply chains.
In April 2023, Gavi CEO Dr Seth Berkley stated:
“It has taken the world more than 50 years to develop a malaria vaccine… Yet this year’s launch serves only as a reminder of what needs to happen now if we are to make malaria vaccines accessible to every child that needs them.”
African public-health agencies are already calling for regional cooperation. The Africa Centres for Disease Control and Prevention (Africa CDC) has urged pooled-procurement mechanisms to increase bargaining power, decrease costs and secure supply. The goal: African countries working together to “own” their malaria-vaccine future rather than waiting on global donor cycles.
For millions of parents across Africa, the malaria vaccine is more than a policy change—it is lifeline. But experts warn: it won’t end malaria on its own. Mosquito nets, improved housing, drainage, early diagnosis and treatment must continue. Climate-change threats like longer mosquito seasons, changing transmission zones add further urgency.
So yes: the vaccine is a tool, but not a silver bullet. Yet for a continent that has lived under malaria’s shadow for centuries, it is a rare chance to shift the story.
In a small health-clinic in rural Uganda, mothers wait for their children’s vaccinations. Many have lost siblings or friends to malaria. The introduction of the vaccine brings more than hope—it brings opportunity to protect the next generation.
Africa’s fight against malaria has always been uphill, challenged by infrastructure, funding and endemic poverty. Now, at last, the vaccine era is here. The rollout of safe, effective malaria vaccines in Africa represents a turning point — one shaped by science, but also by Africa’s own leadership in pursuing health equity.
If implemented well, this campaign could save hundreds of thousands of young lives each year, strengthen primary-health systems, and show that even under pressure, Africa’s health story can change for the better. Because when you protect a child from malaria, you protect the future of a whole community.
.